# Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors

> **NCT05088070** · PHASE1 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 40 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SPH 3348
- **DRUG:** SPH 3348
- **DRUG:** SPH 3348
- **DRUG:** SPH 3348
- **DRUG:** SPH 3348
- **DRUG:** SPH 3348

## Key facts

- **NCT ID:** NCT05088070
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-02
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088070, "Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05088070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*